Two weeks and $20 billion after a major failure in Alzheimer’s disease, Biogen (BIIB) isn’t quite ready to bail on a controversial approach to treating the disorder.

Dr. Michael Ehlers, Biogen’s head of research, said Monday that the company is “looking very closely” at the data on aducanumab, an Alzheimer’s drug meant to slow the disease by targeting sticky brain plaques called beta-amyloid. Last month, Biogen terminated two large studies of aducanumab after determining that the drug had no hope of succeeding. Now Biogen must decide what that failure means for the rest of its work in Alzheimer’s, a ruling Ehlers said will arrive “in the coming weeks.”

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy